Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma - European Journal of Cancer
Moving Beyond 3+3: The Future of Clinical Trial Design | American Society of Clinical Oncology Educational Book
Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study - ScienceDirect
5 Reasons to Invest in Bayesian Dose-Escalation Methods
Early phase clinical trials to identify optimal dosing and safety - ScienceDirect
Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46) - eBioMedicine
![PDF] Dose Escalation Methods in Phase I Cancer Clinical Trials | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2e565a213a4cc812f4610beb8f52eaa028d8bf12/4-Figure2-1.png "PDF] Dose Escalation Methods in Phase I Cancer Clinical Trials | Semantic Scholar")
PDF] Dose Escalation Methods in Phase I Cancer Clinical Trials | Semantic Scholar
Dose intra‐subject escalation to an event (DIETE): A new method for phase 1 dose‐finding utilizing systematic intra‐subject dose escalation with application to T‐cell engagers - Xu - 2021 - Pharmaceutical Statistics -
On Biostatistics and Clinical Trials: Phase I Dose Escalation Study Design: "3 + 3 Design"
Cancers | Free Full-Text | Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Phase I/II Dose-Escalation Trial of Daratumumab for Relapsed/Refractory Multiple Myeloma | Research To Practice
Clinical Trials - Cue Biopharma
Dose escalation. The dose escalation was performed in both intra and... | Download Scientific Diagram
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial - The Lancet
The Classic 3 + 3 Design in Dose-finding Clinical Trials and Its Alternatives | Genpro Research
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method | BMC Cancer | Full Text
exv99w1
Figure 1 | Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors | SpringerLink
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era - ScienceDirect
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era - European Journal of Cancer
Ustekinumab dose escalation: An option for nonresponsive Crohn's? | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Inter-patient and intra-patient dose escalation strategy. Patients were... | Download Scientific Diagram
